Treating depression in coronary artery disease and chronic heart failure: What's new in using selective serotonin re-uptake inhibitors?

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2012, Pages 109-115

  Ioannis, Paraskevaidis ^a   John, Palios ^a   John, Parissis ^a   Gerasimos, Filippatos ^a   Maria, Anastasiou Nana ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cardiovascular disease; Chronic heart failure; Citalopram; Coronary artery disease; Dapoxetine; Depression; Escitalopram; Fluoxetine; Fluvoxamin; Paroxetine; Selective serotonin re uptake inhibitors; Sertraline; Vilazodone

Indexed keywords

NORADRENALIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CARDIAC PATIENT; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HEART RHYTHM; HUMAN; HYPERCOAGULABILITY; HYPERCORTISOLISM; NORADRENALIN BLOOD LEVEL; PROGNOSIS; REVIEW; THROMBOCYTE FUNCTION;

EID: 84860481397     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512800388894     Document Type: Review

References (36)

1. Whooley, M.A. Depression and cardiovascular disease: healing the broken-hearted. JAMA, 2006, 295(24), 2874-2881.
2. Wozniak, G.; Toska, A.; Saridi, M.; Mouzas O. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med. Sci. Monit., 2011, 17(9), 205-214.
3. Paraskevaidis, I.; Parissis, J.T.; Fountoulaki, K.; Filippatos, G.; Kremastinos, D. Selective serotonin re-uptake inhibitors for the treatment of depression in coronary artery disease and chronic heart failure: evidence for pleiotropic effects. Cardiovasc. Hematol. Agents Med. Chem., 2006, 4(4), 361-367.
4. Kimmel, S.E.; Schelleman, H.; Berlin, J.A.; Oslin, D.W.; Weinstein, R.B.; Kinman, J.L.; Sauer, W.H.; Lewis, J.D. The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br. J. Clin. Pharmacol., 2011, 72(3), 514-517.
5. Scherrer, J.F.; Garfield, L.D.; Lustman, P.J.; Hauptman, P.J.; Chrusciel, T.; Zeringue, A.; Carney, R.M.; Freedland, K.E.; Bucholz, K.K.; Owen, R.; Newcomer, J.W.; True, W.R. Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am. J. Med., 2011, 124(4), 318-324.
6. Taylor, D.; Meader, N.; Bird, V.; Pilling, S.; Creed, F.; Goldberg, D. Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy. Br. J. Psychiatry, 2011, 198(3), 179-188.
7. Davidson, K.W.; Kupfer, D.J.; Bigger, J.T.; Califf, R.M.; Carney, R.M.; Coyne, J.C.; Czajkowski, S.M.; Frank, E.; Frasure-Smith, N.; Freedland, K.E.; Froelicher, E.S.; Glassman, A.H.; Katon, W.J.; Kaufmann, P.G.; Kessler, R.C.; Kraemer, H.C.; Krishnan, K.R.; Lespérance, F.; Rieckmann, N.; Sheps, D.S.; Suls, J.M. National Heart, Lung, and Blood Institute Working Group. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom. Med., 2006, 68(5), 645-650.
8. Pizzi, C.; Rutjes, A.W.; Costa, G.M.; Fontana, F.; Mezzetti, A.; Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am. J. Cardiol., 2011, 107(7), 972-979.
9. Santangelo, A.; Testaì, M.; Barbagallo, P.; Crisafulli, C.; Grasso, S.; Manuele, S.; Muscarà, G.; Rizzotto, M.; Tomarchio, M.; Maugeri D. Use of specific serotonin reuptake inhibitors (SSRIs) (Sertraline or Citalopram) in the treatment of depression reduces the cardiovascular risk in the elderly: evidence from a Sicilian population >80 years recovered in the assisted sanitary residences (RSA). Arch. Gerontol. Geriatr., 2009, 48(3), 350-352.
10. Dawood, T.; Lambert, E.A.; Barton, D.A.; Laude, D.; Elghozi, J.L.; Esler, M.D.; Haikerwal, D.; Kaye, D.M.; Hotchkin, E.J.; Lambert G.W. Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk. Hypertens. Res., 2007, 30(4), 285-293.
11. Bismuth-Evenzal, Y.; Gonopolsky, Y.; Gurwitz, D.; Iancu, I.; Weizman, A.; Rehavi, M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J. Affect. Disord., 2012, 136(1-2), 99-103.
12. De Abajo, F.J. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging, 2011, 28(5), 345-367.
13. Tseng, Y.L.; Chiang, M.L.; Huang, T.F.; Su, K.P.; Lane, H.Y.; Lai, Y.C. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb. Res., 2010, 126(6), 517-523.
14. Flöck, A.; Zobel, A.; Bauriedel, G.; Tuleta, I.; Hammerstingl, C.; Höfels, S.; Schuhmacher, A.; Maier, W.; Nickenig, G.; Skowasch D. Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline. Thromb. Res., 2010, 126(2), 83-87.
15. Smoller, J.W.; Allison, M.; Cochrane, B.B.; Curb, J.D.; Perlis, R.H.; Robinson, J.G.; Rosal, M.C.; Wenger, N.K.; Wassertheil-Smoller, S. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch. Intern. Med., 2009, 169(22), 2128-2139.
16. Swenson, J.R.; Doucette, S.; Fergusson, D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can. J. Psychiatry, 2006, 51(14), 923-929.
17. van Zyl, L.T.; Lespérance, F.; Frasure-Smith, N.; Malinin, A.I.; Atar, D.; Laliberté, M.A.; Serebruany, V.L. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. J. Thromb. Thrombolysis, 2009, 27(1), 48-56.
18. Lekakis, J.; Ikonomidis, I.; Papoutsi, Z.; Moutsatsou, P.; Nikolaou, M.; Parissis, J.; Kremastinos, D.T. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int. J. Cardiol., 2010, 139(2), 150-158.
19. Hamer, M.; Batty, G.D.; Marmot, M.G.; Singh-Manoux, A.; Kivimäki, M. Anti-depressant medication use and C-reactive protein: results from two population-based studies. Brain Behav. immun., 2011, 25(1), 168-173.
20. Pizzi, C.; Mancini, S.; Angeloni, L.; Fontana, F.; Manzoli, L.; Costa, G.M. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin. Pharmacol. Ther., 2009, 86(5), 527-532.
21. Le Melledo, J.M.; Mailo, K.; Lara, N.; Abadia, M.C.; Gil L.; Van Ameringen, M.; Baker, G.; Perez-Parada, J. Paroxetine-induced increase in LDL cholesterol levels. J. Psychopharmacol., 2009, 23(7), 826-830.
22. Wei, F.; Crain, A.L.; Whitebird, R.R.; Godlevsky, O.V.; O'Connor, P.J. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs, 2009, 23(10), 857-865.
23. Kamarck, T.W.; Muldoon, M.F.; Manuck, S.B.; Haskett, R.F.; Cheong, J; Flory, J.D.; Vella, E. Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention. Psychoneuroendocrinology, 2011, 36(7), 1070-1079.
24. Briscoe, V.J.; Ertl, A.C.; Tate, D.B.; Davis, S.N. Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes, 2008, 57(12), 3315-3322.
25. Tecco, J.; Monreal, J.; Staner, L. Citalopram may reduce sympathoadrenal hyperactivity in elderly depressed patients: an open multicenter study in Belgium and Luxembourg. Psychiatr. Danub., 2011, 23(Suppl. 1), S35-S42.
26. Spasojevic, N.; Gavrilovic, L.; Jovanovic, P.; Dronjak, S. Flouxetine treatment acts selectively increasing myocardial beta1-adrenoceptor mRNA expression in stress-induced depression. Pharmazie, 2011, 66(8), 611-613.
27. Kowey, P.R.; Mudumbi, R.V.; Aquilina, J.W.; DiBattiste, P.M. Cardiovascular safety profile of dapoxetine during the premarketing evaluation. Drugs R D, 2011, 11(1), 1-11.
28. Tousoulis, D.; Antoniades, C.; Drolias, A.; Stefanadi, E.; Marinou, K.; Vasiliadou, C.; Tsioufis, C.; Toutouzas, K.; Latsios, G.; Stefanadis, C. Selective serotonin reuptake inhibitors modify the effect of beta-blockers on long-term survival of patients with end-stage heart failure and major depression. J. Card. Fail., 2008, 14(6), 456-464.
29. Fosbøl, E.L.; Gislason, G.H.; Poulsen, H.E.; Hansen, M.L.; Folke, F.; Schramm, T.K.; Olesen, J.B.; Bretler D.M., Abildstrøm S.Z.; Sørensen R.; Hvelplund A.; Køber L.; Torp-Pedersen C. Prognosis in heart failure and the value of {beta}-blockers are altered by the use of antidepressants and depend on the type of antidepressants used. Circ. Heart Fail. 2009, 2(6), 582-590.
30. O'Connor, CM.; Jiang, W.; Kuchibhatla, M.; Silva S.G.; Cuffe, M.S.; Callwood, D.D.; Zakhary, B.; Stough, W.G.; Arias, R.M.; Rivelli, S.K.; Krishnan, R. SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J. Am. Coll. Cardiol, 2010, 56(9), 692-699.
31. Pousti, A.; Bakhtiarian, A.; Najafi, R.; Deemyad, T.; Brumand, K.; Hosseini, M.J.; Effect of sertraline on ouabain-induced arrhythmia in isolated guinea-pig atria. Depress Anxiety, 2009, 26(8), 106-110.
32. Stevens, D.L. Duloxetine-associated tachycardia. Ann. Pharmacother., 2008, 42(10), 1511-1513.
33. Coletta, A.P.; Clark A.L.; Cleland, J.G. Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, p-interferon study, BACH, and ATHENA. Eur. J. Heart Fail, 2009, 11(2), 214-219.
34. Jiang, W.; Krishnan, R.; Kuchibhatla, M.; Cuffe, M.S.; Martsberger, C; Arias, R.M., O'Connor, CM.; SADHART-CHF Investigators. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am. J. Cardiol, 2011, 107(4), 545-551.
35. Angermann C.E.; Gelbrich, G.; Störk, S.; Fallgatter, A.; Deckert, J.; Faller, H.; Ertl, G.; MOOD-HF Investigators. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur. J. Heart Fail, 2007, 9(12), 1212-1222.
36. Rivelli, S.; Jiang, W. Depression and ischemic heart disease: what have we learned from clinical trials? Curr. Opin. Cardiol, 2007, 22(4), 286-291.